Depatuxizumab alfa, formerly referred to as ABT-806, represents a unique humanized immunoglobulin targeting the vitronectin associating domain. This therapeutic agent aims to disrupt the formation of the complement membrane attack complex, thus preventing tumor cell spread. Clinical studies have examined its efficacy in managing various oncologi… Read More

Vibostolimab | a | the | this novel | new | emerging antibody | therapeutic | agent represents a | an significant | important | critical advance | step | development in immunotherapy | cancer treatment | therapy. Targeting | focusing | blocking TIGIT, a | an inhibitory | negative | suppressive receptor expressed on | by | in immune | tumor | can… Read More